VKTXViking Therapeutics Inc
VKTX
Viking Therapeutics Inc37,334
Mkt Cap
$4.07BVolume
3.68M52W High
$56.2552W Low
$18.92PE Ratio
-17.01VKTX Fundamentals
Price
$34.27Prev Close
$36.04Open
$37.0250D MA
$32.25Beta
1.41Avg. Volume
4.86MEPS (Annual)
-$1.01P/B
5.68Rev/Employee
$0.00VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Zacks·5h ago
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735 PR Newswire...
PR Newswire·2d ago
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
Zacks·3d ago
Semanteon Capital Management LP Buys New Position in Viking Therapeutics, Inc. $VKTX
Semanteon Capital Management LP purchased a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) in the second quarter, according to the company in its most recent 13F filing with...
MarketBeat·3d ago
Viking Therapeutics, Inc. $VKTX Shares Bought by Persistent Asset Partners Ltd
Persistent Asset Partners Ltd grew its holdings in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 88.8% in the second quarter, according to its most recent filing with the...
MarketBeat·4d ago
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Zacks·6d ago
Canaccord Genuity Group Issues Positive Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price
Canaccord Genuity Group increased their price objective on shares of Viking Therapeutics from $106.00 to $107.00 and gave the stock a "buy" rating in a research report on Wednesday...
MarketBeat·7d ago
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks·8d ago
Can NVO's Ozempic, Wegovy Sales Improve in 2026 After a Subdued Q3?
Novo Nordisk eyes a 2026 comeback as it slashes jobs, cuts U.S. semaglutide prices and focuses on expanding the reach of key drugs after a weak Q3.
Zacks·8d ago